
Pharmacally
systemic lupus erythematosus
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in systemic lupus erythematosus
Clinical TrialsBeeline’s Afimetoran Meets Phase 2 Endpoint in SLEBeeline Medicines’ investigational oral TLR7/8 inhibitor afimetoran met the primary endpoint in a 248-patient Phase 2 trial in systemic lupus erythematosus, with all three dose groups achieving significantly…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.